10 Cash-Rich Undervalued Stocks To Invest In

5. Genmab A/S (NASDAQ:GMAB)

P/E Ratio as of March 3: 13.26

TTM Operating Cash Flow as of December 31, 2024: $7,771,000,000

Number of Hedge Fund Holders: 19

Danish biotechnology company, Genmab A/S (NASDAQ:GMAB) specializes in antibody-based treatments for lymphoma, cervical cancer, multiple myeloma, thyroid eye disease, multiple sclerosis, and hemophilia. On February 20, the company announced that Japan has approved EPKINLY (epcoritamab) to treat follicular lymphoma (FL) in patients who have already tried at least two other treatments. This makes EPKINLY the first injectable antibody in Japan approved for both FL and other similar cancers. The approval is based on studies showing it works safely and effectively.

Genmab A/S (NASDAQ:GMAB) had a great year in 2024, with revenue jumping 31%, supported by the commercial success of its medicines like EPKINLY and TIVDAK. Even after significant investments, like acquiring ProfoundBio for $1.8 billion and spending $500 million on share buybacks, the company still ended the year with nearly $3 billion in cash. This strong financial position means GMAB can continue investing in new treatments while keeping the business growing.

Among the hedge funds tracked by Insider Monkey, 19 funds were bullish on Genmab A/S (NASDAQ:GMAB) at the end of Q4 2024, compared to 14 funds in the prior quarter. Ken Griffin’s Citadel Investment Group was the leading stakeholder of the company, with 3 million shares worth $64.5 million.